التفاصيل البيبلوغرافية
| العنوان: |
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group |
| المؤلفون: |
Fatma Gül Demirkan (11717446), Kadir Ulu (11717449), Kübra Öztürk (11717452), Şerife Gül Karadağ (11717455), Semanur Özdel (11717458), Hafize Emine Sönmez (11717461), Figen Çakmak (11717464), Ferhat Demir (11717467), Betül Sözeri (689729), Nuray Aktay Ayaz (11717470) |
| سنة النشر: |
2021 |
| المجموعة: |
Smithsonian Institution: Digital Repository |
| مصطلحات موضوعية: |
Medicine, Pharmacology, Biotechnology, Ecology, Immunology, Mental Health, Adalimumab, biosimilar, amgevita, juvenile idiopathic arthritis, ABP-501 |
| الوصف: |
To review the real-life data, to provide an input to the literature concerning treatment of juvenile idiopathic arthritis (JIA) with adalimumab (ADL) biosimilar. This multi-centric retrospective study was conducted among children with JIA, followed up for at least 24-weeks from the initiation of ADL biosimilar (ABP 501) treatment. Adverse events and alterations in disease activity scores were figured out. The median age of the group was 15.5 (5–18) years. JIA categories were oligoarticular (n =12), enthesitis-related (ERA) (n=24), psoriatic (PsA) (n=6), and polyarticular (n=4). Uveitis was detected at the initiation of the disease (n=3), during the disease course (n=5), or before the diagnosis (n=1). The first-line treatment preferences were ADL biosimilar (n=37) and etanercept (n=9). On the 6th month of ABP 501, 40 (86.9%) patients had achieved complete remission. Six patients (1 PsA, 1 polyarticular JIA, and 4 ERA) had ongoing active arthritis. Furthermore, all except one of the patients had remission of ophthalmologic findings. No life-threatening adverse events were observed. ABP 501 has a gradual increase in prescription in pediatric rheumatology. Real-life data of the cohort announce that ADL biosimilar is a suitable and effective treatment option for patients with JIA in case of indication. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/journal_contribution/Toward_the_integration_of_biosimilars_into_pediatric_rheumatology_adalimumab_ABP_501_experience_of_PeRA_research_group/17031748Test |
| DOI: |
10.6084/m9.figshare.17031748.v1 |
| الإتاحة: |
https://doi.org/10.6084/m9.figshare.17031748.v1Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.F953FACE |
| قاعدة البيانات: |
BASE |
